Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Obesity has been recognized as a global epidemic and public health crisis. The prevalence of obesity has tripled since 1975, especially in the elderly population. Accumulating preclinical and clinical studies have confirmed that chronic low-grade inflammation of adipose tissues is mechanistically related to metabolic diseases and tissue complications in overweight and obesity patients, as a result of the intricate interplay of various pro-inflammatory and anti-inflammatory signaling cascades. The present study aims to explore the differential expressions of receptor activator of nuclear factor-kappa B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in leukocytes of elderly obesity patients in Xinjiang, thereby providing new physiological, cellular, and molecular targets for the treatment of obesity.
Methods: A total of 40 obesity patients and 40 non-obesity patients were selected. The protein and gene expression levels of RANK, RANKL, and OPG in peripheral blood were detected by western blotting and real-time quantitative PCR.
Results: There was no significant difference in the expression levels of RANK protein, OPG protein, and OPG gene between the obesity group and non-obesity group ( > 0.05). The relative expression levels of the RANK gene and RANKL protein and gene were significantly different between the obesity group and non-obesity group ( < 0.05). The differential expressions of the RANK gene, RANKL protein and gene, and the OPG protein in leukocytes had a significant correlation with obesity in the elderly population ( < 0.05).
Conclusion: The expressions of the RANKL protein and gene and RANK gene in leukocytes of elderly obesity patients in Xinjiang were higher than those of non-obesity patients. In the elderly obesity patients in Xinjiang, the abdominal circumference was correlated with the expressions of the RANK gene, RANKL protein and gene, and OPG protein in leukocytes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355355 | PMC |
| http://dx.doi.org/10.1515/med-2025-1196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].
Rev Med Liege
September 2025
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. Tirzepatide tolerance is almost similar to that of pure GLP-1 receptor agonists, with digestive adverse events, most often during the first weeks after initiation, which justifies the recommendation of progressive titration every four weeks.
View Article and Find Full Text PDF[Screening for sleep apnea-hypopnea syndrome : data from Liège University Hospital Center with a mandibular movement measurement device (Brizzy].
Rev Med Liege
September 2025
Service de Pneumologie, CHU de Liège, Belgique.
Obstructive sleep apnea-hypopnea syndrome (OSAHS) is an underrated and heavy public health problem. Polysomnography (PSG) remains GOLD-standard examination but we also use ambulatory screening tests including Brizzy, which measures mandibular movements. The aim is to report on our experience with the Brizzy and compare it with PSG data.
View Article and Find Full Text PDF[Focus on bariatric endoscopy in Belgium].
Rev Med Liege
September 2025
Service de Gastroentérologie, CHU Liège, Belgique.
Bariatric endoscopy is an increasingly recognized alternative to surgery for obesity treatment. Recent guidelines from leading medical societies (IFSO, ASMBS, ASGE, ESGE) have included endoscopic sleeve gastroplasty (ESG) and the intragastric balloon (IGB) in their recommendations. These procedures are indicated for patients with a body mass index (BMI) between 27 and 40 kg/m² who cannot or do not wish to undergo surgery.
View Article and Find Full Text PDFVariation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England.
Clin Obes
September 2025
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level. This study aimed to assess the commissioning and availability of services and obesity medications across England.
View Article and Find Full Text PDFExploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.
Obes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.